Skip to content
SFN info

Varicella zoster virus (vzv) and Small Fiber Neuropathy (SFN)

Varicella zoster virus (VZV)

Description:

Varicella zoster virus (VZV) is a highly contagious virus that causes two distinct diseases: varicella (chickenpox) and herpes zoster (shingles). Varicella is the primary infection that occurs when a person is first exposed to the virus, usually in childhood. After the primary infection, VZV remains dormant in the body’s nerve tissues and can reactivate later in life to cause herpes zoster.

Prevalence:

Varicella zoster virus is prevalent worldwide. Before the introduction of the varicella vaccine, nearly all individuals in temperate climates had been infected by the age of 20. Even with vaccination, VZV is still common, with millions of cases of chickenpox and shingles reported each year.

Risk Factors:

Risk factors for developing VZV include:

  • Age: Varicella is most common in children, while herpes zoster is more common in adults over the age of 50.
  • Immunocompromised status: Individuals with weakened immune systems are at a higher risk of both primary infection and reactivation of the virus.
  • Lack of vaccination: Those who have not received the varicella or shingles vaccine are at a higher risk of infection.

Prognosis:

Varicella is generally a mild disease in children but can be severe in adults and immunocompromised individuals. Complications can include bacterial superinfection of skin lesions, pneumonia, and encephalitis.

Herpes zoster can cause significant pain and discomfort, and in some cases, it can lead to postherpetic neuralgia, a condition where the pain persists even after the rash has cleared. Other complications can include ocular involvement, neurological complications, and skin infections.

Prevention:

Prevention of VZV is primarily through vaccination. The varicella vaccine is recommended for all children and non-immune adults, while the herpes zoster vaccine is recommended for adults over the age of 50.

Epidemiology:

The prevalence of VZV varies by region, age, and gender. In temperate climates, varicella is primarily a disease of childhood, while in tropical climates, infection tends to occur at older ages. Herpes zoster is more common in older adults and in those with weakened immune systems. There is no significant gender difference in the prevalence of VZV.

Association between Varicella zoster virus (VZV) and Small Fiber Neuropathy (SFN)

Association:

Varicella zoster virus (VZV) is known to cause chickenpox and shingles. It has been linked to small fiber neuropathy (SFN) through the following mechanisms:

  • Neuronal damage: VZV can cause damage to the neurons, including small fibers, leading to neuropathy. This is often seen in cases of postherpetic neuralgia, a complication of shingles where the pain continues even after the rash has healed.

  • Inflammatory response: The body’s immune response to VZV can lead to inflammation that damages the small fibers. This inflammation can persist even after the acute infection has resolved, leading to SFN.

  • Viral persistence: VZV remains dormant in the body after the initial infection and can reactivate later in life. This reactivation can cause damage to the small fibers, leading to SFN.

Research Updates:

Recent research continues to explore the link between VZV and SFN. Some key findings include:

  • A study published in the Journal of Neurology in 2018 found that VZV DNA could be detected in the skin of some patients with SFN, suggesting a possible role of the virus in the disease.

  • A 2020 study in the journal Pain reported that patients with SFN had significantly higher levels of antibodies against VZV compared to healthy controls. This suggests that a past VZV infection could be a risk factor for SFN.

  • A 2021 study in the Journal of Pain Research found that treatment with antiviral drugs could improve symptoms in some patients with SFN, suggesting that viral infections like VZV may play a role in the disease.

These findings suggest that VZV may be involved in the pathogenesis of SFN, but more research is needed to fully understand this relationship.

Symptoms of Varicella zoster virus (VZV)

List of Symptoms:

Varicella zoster virus (VZV) is responsible for two distinct diseases: chickenpox (varicella) and shingles (herpes zoster). The symptoms for each are different:

  • Chickenpox (Varicella):

    • Fever
    • Tiredness
    • Loss of appetite
    • Headache
    • Rash that turns into itchy, fluid-filled blisters that eventually turn into scabs

  • Shingles (Herpes Zoster):

    • Pain, burning, numbness or tingling
    • Sensitivity to touch
    • A red rash that begins a few days after the pain
    • Fluid-filled blisters that break open and crust over
    • Itching

Some people may also experience:

  • Fever
  • Headache
  • Sensitivity to light
  • Fatigue

In terms of small fiber neuropathy (SFN), it is known that VZV can lead to postherpetic neuralgia (PHN), a condition that affects nerve fibers and skin, and can cause severe pain. PHN is a type of small fiber neuropathy.

Severity:

The severity of symptoms can vary greatly. Chickenpox is usually mild but can be severe in infants, adults, and people with weakened immune systems. Shingles can be quite painful, and the pain can last for weeks or even months after the rash has healed. Postherpetic neuralgia, which can follow shingles, can cause severe pain that can interfere with sleep and daily activities.

Onset:

For chickenpox, symptoms typically appear 10 to 21 days after exposure to the virus. The rash is often the first sign of the disease, followed by the other symptoms.

For shingles, the first symptom is often pain, followed by the rash. The rash usually appears a few days after the pain begins. Postherpetic neuralgia can develop after the shingles rash has healed.

Diagnosis of Varicella zoster virus (VZV)

Methods:

Diagnosis of Varicella zoster virus (VZV) is typically based on the clinical presentation of the disease. However, laboratory testing can be used to confirm the diagnosis. Here are some common methods:

  • Clinical Diagnosis: The distinctive rash and pattern of breakouts in chickenpox and shingles are often enough to diagnose VZV.
  • PCR Testing: Polymerase chain reaction (PCR) testing is the most reliable method for diagnosing VZV. This test identifies the virus’s DNA in fluid taken from the rash blisters.
  • Direct Fluorescent Antibody Testing: This test uses fluorescent dyes to detect VZV antigens in cells taken from the rash.
  • Serology: Blood tests can detect antibodies to VZV. These tests can determine if a person is immune to chickenpox or if an infection is recent.

Differential Diagnosis:

Several conditions can present similarly to VZV and should be considered in the differential diagnosis:

  • Herpes Simplex Virus (HSV): This virus can cause similar skin lesions, but they are usually localized to one area of the body.
  • Hand, Foot, and Mouth Disease: This condition can cause a rash similar to chickenpox, but it is usually accompanied by mouth sores.
  • Scabies or Insect Bites: These can cause itchy bumps that may be mistaken for chickenpox.
  • Drug Reactions: Some drug reactions can cause a rash that looks similar to chickenpox or shingles.

Limitations:

There are several limitations and challenges in diagnosing VZV:

  • Atypical Presentations: VZV can sometimes present without the typical rash, making diagnosis difficult.
  • Overlapping Symptoms: Many conditions can cause similar symptoms, such as rashes or blisters, which can lead to misdiagnosis.
  • Testing Limitations: While PCR testing is highly accurate, it requires a sample from the rash, which may not be available if the rash is absent or has already healed.
  • Immunity Status: Serology tests can determine if a person is immune to chickenpox, but they cannot confirm a current infection.

Treatments for Varicella zoster virus (VZV)

Options:

Varicella zoster virus (VZV) causes two distinct clinical conditions: varicella (chickenpox) and herpes zoster (shingles). The treatment options differ for each condition and can include:

  • Antiviral Medications: These are the primary treatment for VZV infections, especially in high-risk individuals. Medications such as acyclovir, valacyclovir, and famciclovir are commonly used. These drugs can help reduce the severity and duration of symptoms.

  • Pain Management: For herpes zoster, pain management is a crucial aspect of treatment. This can include over-the-counter pain relievers, prescription nonsteroidal anti-inflammatory drugs (NSAIDs), or even opioids in severe cases. Topical creams or patches containing capsaicin or a local anesthetic may also be used.

  • Vaccines: The varicella vaccine is used to prevent chickenpox, and the zoster vaccine is used to prevent shingles. These vaccines are especially important for individuals at high risk of complications from VZV infections.

When VZV is linked to small fiber neuropathy (SFN), the treatment approach may also include managing the neuropathic pain associated with SFN. This can involve medications such as gabapentin or pregabalin.

Effectiveness:

Antiviral medications are effective at reducing the severity and duration of VZV infections if started within 72 hours of symptom onset. Pain management strategies can help control the pain associated with herpes zoster, and vaccines are effective at preventing VZV infections.

In the context of SFN, managing the neuropathic pain can help improve quality of life, but it does not treat the underlying VZV infection.

Side Effects:

  • Antiviral Medications: Side effects can include nausea, vomiting, headache, and dizziness. In rare cases, these medications can cause kidney problems.

  • Pain Management Medications: Side effects can range from mild (such as constipation or drowsiness) to severe (such as addiction or overdose, especially with opioids).

  • Vaccines: Side effects are usually mild and can include pain and swelling at the injection site, fever, and rash.

Recent Advancements:

A newer shingles vaccine, called Shingrix, has been developed and is recommended over the older Zostavax vaccine. Shingrix is more than 90% effective at preventing shingles and postherpetic neuralgia, a common complication of shingles. This vaccine is given in two doses, with the second dose given 2 to 6 months after the first.